Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the…
ATSN-101 demonstrated clinically meaningful improvements in vision with no drug-related serious adverse events Data presented at the American Academy of Ophthalmology 2022 Annual Meeting DURHAM, N.C., Oct. 03, 2022 (GLOBE NEWSWIRE) --…